Closure of Trading Window
Trading Window for dealing in Company's shares will remain closed for the Company's insiders from today i.e. 19th May, 2017 (commencing from the time of above intimation to the Stock Exchanges) till Forty-Eight hours after the announcement of the Financial Results on 29th May, 2017. Updates
The Company has received "Certificate of GMP Compliance of a Manufacturer" from Australian Government, Department of Health, Therapeutic Goods Administration. Shareholding for the Period Ended March 31, 2017
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here Certificate Pursuant To Regulation 40 (9) Of SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015 For Half Year Ended March 31, 2017.
Certificate pursuant to Regulation 40 (9) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 for half year ended March 31, 2017. Compliance Certificate For The Period Ended 31St March, 2017
Compliance Certificate Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the period ended 31st March, 2017. Statement Of Investor Complaints For The Quarter Ended 31St March, 2017
Statement of Investor Complaints for the quarter ended 31st March, 2017 under Regulation 13(3) of SEBI (LODR), 2015.
Marksans Pharma facility receives four observations from US FDA
Drug company Marksans Pharma today said that the FDA, the US health regulator has issued four observations, none of them critical, after completing the inspection of its Verna manufacturing unit in Goa. Previously UK's drug regulator has conducted an inspection of the same Verna facility in February this year, and had no observations. Marksans shares have been trading up on the news that the FDA has granted final approval for Marksan's application for Dutasteride Soft Gelatin Capsules, which is generically equivalent to Avodart capsules by GlaxoSmithKline. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. The company said that it planned to launch the product immediately in the US market. Marksans Pharma up 20% after inspection wind-up at Goa plant
Marksans Pharma today zoomed 20 per cent after the company said inspection by the UK health regulator at its Goa plant has been completed without any critical observations. The stock sky-rocketed...